DealPulse Signal Wk 42: STERIS Paid $2.1 Billion for Surgical Consumables, and No Drug Made the Top Five
The top five upfronts bought pads, skincare, labs, a robot and pathology software. Three AI licences paid 3.4% upfront.
Athithi Verma
ESMO 2026 Preview: Seven of Twelve Presidential Abstracts Have Already Claimed a Survival Win
Direction is known for ten of twelve Presidential readouts. Size is sealed, and ADCs face the survival test again.
OrphanPulse Wk 41: BridgeBio Won Priority Review for the First Oral Achondroplasia Drug
Infigratinib would be the first oral achondroplasia drug, against a daily injection and a weekly one already on the market.
NeuroPulse Wk 41: Teva Took the Three-Hour Wait Out of Long-Acting Olanzapine
The intramuscular olanzapine depot needs three hours of monitoring after every injection. Teva’s monthly version needs none.
DealPulse Signal Wk 41: McKesson Bought Into Home Infusion and Shionogi Bought the Next Label
Three takeovers lifted paid at signing to 80%. Four licences paid 17%, and a profit split carried the rest of the risk.
The FTC Warned 24 Large Healthcare Companies That Following CMS Price Rules Is No Shield Against a Deception Case
A hospital can meet every CMS posting rule and still face an FTC deception case over the estimate a patient receives.
One Price in Japan, Response-Linked Payments in Australia and No Public Price in China: In Asia-Pacific the Payer Sets the CAR-T Price
One price in Japan, response-linked payments in Australia, no public price in China: CAR-T sponsors face three markets.
CMS Set December 2027 for Insurers’ Prescription Drug Price Files, a Requirement on Hold Since 2021
The drug file reaches manufacturers, and the schema due around May 2027 decides how much net price becomes public.
Only one Member State was assessing each valve when Brussels chose them, so the joint report will frame the evidence.
Only one Member State was assessing each valve when Brussels chose them, so the joint report will frame the evidence.
Korea’s First Homegrown GLP-1 Cut Weight 9.75% at 40 Weeks, So Hanmi Will Fight Wegovy and Mounjaro on Price and Supply
Hanmi’s GLP-1 trails Wegovy and Mounjaro on weight loss, so its case rests on a low starting price and Korean supply.